REDWOOD CITY, Calif., April 28, 2014 /CNW/ - Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Michael A. Fleming as Senior Vice President, Commercial Strategy. Mr. Fleming joins Coherus with more than 25 years of experience in strategic and operational leadership roles at preeminent biotech companies.
"Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, President and CEO of Coherus. "Our pipeline is now sufficiently advanced to begin evaluating our strategic options for commercialization. Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance. He will play a key role in defining strategies that effectively maximize the commercial potential of our products."
"I am excited to join the strong, highly-experienced team at Coherus," said Mr. Fleming. "I believe Coherus' unique business model and comprehensive, cutting-edge capabilities are perfectly aligned to meet the enormous market opportunity for high-quality, cost-effective biosimilars."
Mr. Fleming has extensive experience in the biopharmaceutical industry, including senior leadership or executive management roles with Elan Corporation, Nuvelo, Inc., Genentech, Inc., GlaxoSmithKline, SmithKline Beecham, and inVentiv Health. Michael has been instrumental in the launch, commercialization, and business development of numerous products in various therapeutic areas including HIV, infectious diseases, diabetes, CNS, multiple sclerosis, cardiovascular, and oncology. Michael earned a Microbiology Specialist Degree (BSc) from the University of Toronto, Victoria College, and an MBA from the Rotman School of Business, University of Toronto.
About Coherus Biosciences
Coherus Biosciences is a leading biologics platform company focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medications worldwide. Headquartered in the San Francisco Bay Area and founded by a group of biotech pioneers who helped build America's first generation biotherapeutics industry, Coherus has developed a unique, collaborative business model that leverages a strategic consortium of key service providers aligned through ownership and shared incentives. Coherus' global commercialization partnerships include top tier biopharma companies in Europe, Asia, and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.
Contact: Beth Jimison, 650-649-3526, firstname.lastname@example.org
SOURCE: Coherus Biosciences, Inc.
For further information: